title: Efficacy of paclitaxel-eluting stent in patients with impaired glucose tolerance--comparison with sirolimus-eluting stent.
abstract: BACKGROUND
  Experimental and clinical studies have shown that paclitaxel-eluting stent (PES) attenuates the effect of diabetes on re-stenosis after percutaneous coronary intervention. Although impaired glucose tolerance (IGT) is a pre-diabetic phase characterized as post-prandial hyperglycemia and hyperinsulinemia, the efficacy of PES in these pre-diabetic patients remains unknown. The purpose of the present study was therefore to compare the efficacy of PES in IGT patients with that of sirolimus-eluting stent (SES).
  
  
  RESULTS
  A total of 370 IGT patients with coronary artery disease were examined (SES, n=229; PES, n=141). The incidence of major adverse cardiovascular events (MACE; all-cause death, non-fatal myocardial infarction or repeat revascularization) was compared between the 2 groups. The PES group had lower body mass index, total cholesterol and low-density lipoprotein cholesterol levels and higher prevalence of previous myocardial infarction than the SES group. The incidence of repeat revascularization in the PES group was similar to that in the SES group (22% vs. 19%, P=0.71). The incidence of hard cardiac events such as all-cause death and non-fatal myocardial infarction were also similar between the 2 groups. Finally, there were no significant differences in MACE between the SES and PES groups (23% vs. 21%, P=0.76).
  
  
  CONCLUSIONS
  In patients with IGT, the efficacy of PES was similar to that of SES, and any advantage of PES over SES was not observed in these pre-diabetic patients.
authors.affiliation: Department of Cardiology, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita 565-8565, Japan. kataoky@ccf.org
authors.forename: Yu
authors.initials: Y
authors.lastname: Kataoka
authors.forename: Nobuhito
authors.initials: N
authors.lastname: Yagi
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Kokubu
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Kasahara
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Abe
authors.forename: Yoritaka
authors.initials: Y
authors.lastname: Otsuka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000494:pharmacology*; D015992:Body Mass Index; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000494:pharmacology*; D011446:Prospective Studies; D020123:Sirolimus / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D008078:Cholesterol, LDL; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus